Results 201 to 210 of about 167,789 (348)
The micropeptide altH19 interacts with phosphorylated CDK2 (p‐CDK2), subsequently activating CDK2 phosphorylation. This enhances the downstream E2F1 target gene RB activity, which accelerates DNA replication, ultimately leading to rapid myeloma cell mitosis and proliferation.
Yaxin Zhang +6 more
wiley +1 more source
LncRNA SNHG1 Knockdown Ameliorates HIV-1 gp120V3 Loop-Induced Microglial Neuroinflammation by Regulating the Autophagy Process. [PDF]
Yan X +12 more
europepmc +1 more source
Non‐coding RNAs (ncRNAs) regulate breast cancer radioresistance via cell cycle, DNA repair and tumour microenvironment pathways. Targeting ncRNAs (e.g., HOTAIR and miR‐155) with RNA‐based therapies (ASOs and CRISPR) shows promise but faces delivery challenges.
Xiaohui Zhao +8 more
wiley +1 more source
Bioinformatic Analysis of Differentially Expressed Long Non-Coding RNAs in Skeletal Muscle Following Aerobic and Resistance Exercise. [PDF]
Régnier K +5 more
europepmc +1 more source
The pathogenic mechanisms of pulmonary vascular endothelial cells (VECs) in lung diseases and their multimodal therapeutic strategies. ABSTRACT Pulmonary vascular endothelial cells (VECs) are essential for the normal function of the lung, through maintaining vascular barrier integrity, regulating blood flow, and participating in inflammatory responses ...
Qianyue Liu +5 more
wiley +1 more source
Long non-coding RNAs and therapeutic resistance in multiple myeloma: from molecular insights to clinical applications. [PDF]
Safari MH +12 more
europepmc +1 more source
We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang +12 more
wiley +1 more source

